SOPHiA GENETICS SA operates a cloud-native data analytics platform focused on healthcare diagnostics, backed by exclusive patent licenses expiring in 2033. Despite robust partnerships, including a pivotal multi-year Microsoft agreement, the company continues to report material net losses while managing $50 million in term loans with provisions for additional debt tranches. Its growth hinges on broadening platform adoption across healthcare ecosystem partners and expanding diagnostic product commercialization, yet faces risks from license obligations, supplier dependencies, and interest rate fluctuations. Capital allocation favors operational funding over shareholder returns, with no dividends or buybacks recorded.